Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 71
The GLP-1 segment accounts for 3% of total diabetes care
market value in Region AAMEO
GLP-1 value
in bDKK
Region AAMEO GLP-1 market
VictozaⓇ
exenatide
VictozaⓇ value market share in Region AAMEO
VictozaⓇ
exenatide
▪dulaglutide
lixisenatide
dulaglutide Share of total
lixisenatide diabetes care
GLP-1 value
market share
market
0.6
3%
100%
0.5
CAGR value¹: 27.2%
80%
0.4
- 2%
60%
0.3
40%
0.2
- 1%
0.1
20%
0.0
0%
0%
Nov
2012
Nov
2017
Nov
2012
1 CAGR for 5-year period
AAMEO: Africa, Asia, the Middle East and Oceania
Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 value figures (DKK)
changing
diabetes
Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 value figures (DKK)
.49%
33%
-17%
1%
Nov
2017
novo nordiskView entire presentation